Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
29
05
2023
accepted:
28
08
2023
medline:
12
10
2023
pubmed:
10
10
2023
entrez:
10
10
2023
Statut:
epublish
Résumé
Talaromyces marneffei (T. marneffei) is an opportunistic fungal infection (talaromycosis), which is common in subtropical regions and is a leading cause of death in HIV-1-infected patients. This study aimed to determine the characteristics and risk factors associated with hospital readmissions in HIV patients with T. marneffei infection in order to reduce readmissions. We conducted a retrospective study of admitted HIV-infected individuals at the Fourth People's Hospital of Nanning, Guangxi, China, from 2012 to 2019. Kaplan-Meier analyses and Principal component analysis (PCA) were used to evaluate the effects of T. marneffei infection on patient readmissions. Additionally, univariate and multifactorial analyses, as well as Propensity score matching (PSM) were used to analyze the factors associated with patient readmissions. HIV/AIDS patients with T. marneffei-infected had shorter intervals between admissions and longer lengths of stay than non-T. marneffei-infected patients, despite lower readmission rates. Compared with non-T. marneffei-infected patients, the mortality rate for talaromycosis patients was higher at the first admission. Among HIV/AIDS patients with opportunistic infections, the mortality rate was highest for T. marneffei at 16.2%, followed by cryptococcus at 12.5%. However, the readmission rate was highest for cryptococcus infection (37.5%) and lowest for T. marneffei (10.8%). PSM and Logistic regression analysis identified leukopenia and elevated low-density lipoprotein (LDL) as key factors in T.marneffei-infected patients hospital readmissions. The first admission represents a critical window to intervene in the prognosis of patients with T. marneffei infection. Leukopenia and elevated LDL may be potential risk factors impacting readmissions. Our findings provide scientific evidence to improve the long-term outcomes of HIV patients with T. marneffei infection.
Identifiants
pubmed: 37816066
doi: 10.1371/journal.pntd.0011622
pii: PNTD-D-23-00667
pmc: PMC10564132
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011622Informations de copyright
Copyright: © 2023 Shi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no conflict of interest exists.
Références
Lancet. 1994 Jul 9;344(8915):110-3
pubmed: 7912350
Top Antivir Med. 2020 Jan;27(4):102-105
pubmed: 32224501
Int J Gen Med. 2018 Apr 09;11:127-141
pubmed: 29670391
Infection. 2022 Feb;50(1):169-178
pubmed: 34351597
Clin Infect Dis. 2013 May;56(9):1273-9
pubmed: 23386634
Pan Afr Med J. 2019 Oct 11;34:79
pubmed: 31934222
Mycoses. 2021 Oct;64(10):1203-1212
pubmed: 33971053
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):117-125
pubmed: 27787346
N Engl J Med. 1998 Dec 10;339(24):1739-43
pubmed: 9845708
J Travel Med. 2014 Jul-Aug;21(4):292-4
pubmed: 24816045
Emerg Infect Dis. 2020 Sep;26(9):2137-2147
pubmed: 32818410
Clin Microbiol Infect. 2015 May;21(5):484-9
pubmed: 25677258
Curr HIV/AIDS Rep. 2014 Sep;11(3):279-90
pubmed: 24966138
Clin Chim Acta. 2016 Jun 1;457:46-53
pubmed: 27034055
Front Med (Lausanne). 2022 Jul 27;9:930678
pubmed: 36250101
J Fungi (Basel). 2022 Apr 28;8(5):
pubmed: 35628715
Clin Microbiol Infect. 2019 Feb;25(2):233-241
pubmed: 29698815
Chin Med J (Engl). 2019 Aug 20;132(16):1909-1918
pubmed: 31348027
PLoS Negl Trop Dis. 2022 May 4;16(5):e0010388
pubmed: 35507586
PLoS Negl Trop Dis. 2019 Nov 25;13(11):e0007837
pubmed: 31765380
Clin Infect Dis. 1996 Jul;23(1):125-30
pubmed: 8816141
Eur J Clin Microbiol Infect Dis. 2023 Jan;42(1):113-120
pubmed: 36413338
Chin Med J (Engl). 2016 May 5;129(9):1059-65
pubmed: 27098791
CMAJ. 2020 Jan 27;192(4):E92-E95
pubmed: 31988153
J Clin Epidemiol. 1990;43(2):153-7
pubmed: 2303845
Mycopathologia. 2019 Dec;184(6):709-720
pubmed: 31811603
Expert Rev Clin Pharmacol. 2018 May;11(5):507-517
pubmed: 29595351
Int J STD AIDS. 2022 Apr;33(5):433-441
pubmed: 35239420
Trends Microbiol. 2014 Mar;22(3):120-7
pubmed: 24530175
J Healthc Manag. 2018 Sep-Oct;63(5):e100-e114
pubmed: 30180036
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):e90-e98
pubmed: 28291051
Clin Diabetes Endocrinol. 2017 Mar 22;3:3
pubmed: 28702257
Tohoku J Exp Med. 2018;244(3):231-242
pubmed: 29563388